Behçet syndrome: from pathogenesis to novel therapies

Clinical and Experimental Medicine

Volumn 16, Issue 1, 2016, Pages 1-12

  Mazzoccoli, Gianluigi ^a   Matarangolo, Angela ^a   Rubino, Rosa ^a   Inglese, Michele ^a   De Cata, Angelo ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Aphthae; Arthritis; Beh et; Immunosuppression; Uveitis; Vasculitis

Indexed keywords

ANTICOAGULANT AGENT; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT;

BEHCET SYNDROME; HUMAN; PATHOLOGY; TREATMENT OUTCOME;

ANTICOAGULANTS; BEHCET SYNDROME; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TREATMENT OUTCOME;

EID: 84957945347     PISSN: 15918890     EISSN: 15919528     Source Type: Journal    
DOI: 10.1007/s10238-014-0328-z     Document Type: Review

References (220)

1. Yazici H, Yazici Y. Criteria for Behçet’s disease with reflections on all disease criteria. J Autoimmun. 2014;48–49:104–7. doi:10.1016/j.jaut.2014.01.014.
2. Lehner T. Immunopathogenesis of Behcet’s disease. Ann Med Interne (Paris). 1999;150(6):483–7.
3. Ambrose NL, Haskard DO. Differential diagnosis and management of Behçet syndrome. Nat Rev Rheumatol. 2013;9(2):79–89.
4. Chambers JC, Haskard DO, Kooner JS. Vascular endothelial function and oxidative stress mechanism in patients with Behcet’s syndrome. J Am Coll Cardiol. 2000;37:517–20.
5. Mehta P, Laffan M, Haskard DO. Thrombosis and Behçet’s syndrome in non-endemic regions. Rheumatology (Oxford). 2010;49(11):2003–4.
6. Yazici Y, Yazici H. Behcet’s syndrome. Curr Rheumatol Rep. 2010;12(6):429–35.
7. International Team for the Revision of the International. Criteria for Behçet’s Disease (ITR-ICBD). The International Criteria for Behçet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28(3):338–47.
8. Faezi ST, Paragomi P, Shahram F, et al. Clinical features of Behcet’s disease in patients without oral aphthosis. Mod Rheumatol. 2014;24(4):637–9.
9. O’Neill TW, Rigby AS, Silman AJ, Barnes C. Validation of the International Study Group criteria for Behçet’s disease. Br J Rheumatol. 1994;33(2):115–7.
10. Calamia KT, Wilson FC, Icen M, Crowson CS, Gabriel SE, Kremers HM. Epidemiology and clinical characteristics of Behçet’s disease in the US: a population-based study. Arthritis Rheum. 2009;61:600–4.
11. Direskeneli H. Behçet’s disease: infectious aetiology, new autoantigens, and HLA-B51. Ann Rheum Dis. 2001;60:996–1002.
12. Gül A, Hajeer AH, Worthington J, Barrett JH, Ollier WE, Silman AJ. Evidence for linkage of the HLA-B locus in Behçet’s disease, obtained using the transmission disequilibrium test. Arthritis Rheum. 2001;44:239–40.
13. de Menthon M, Lavalley MP, Maldini C, Guillevin L, Mahr A. HLA-B51/B5 and the risk of Behçet’s disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum. 2009;61:1287–96.
14. Arber N, Klein T, Meiner Z, Pras E, Weinberger A. Close association of HLA-B51 and B52 in Israeli patients with Behçet’s syndrome. Ann Rheum Dis. 1991;50:351–3.
15. Salvarani C, Boiardi L, Mantovani V, et al. Association of MICA alleles and HLA-B51 in Italian patients with Behçet’s disease. J Rheumatol. 2001;28:1867–70.
16. Kötter I, Günaydin I, Stübiger N, et al. Comparative analysis of the association of HLA-B*51 suballeles with Behçet’s disease in patients of German and Turkish origin. Tissue Antigens. 2001;58:166–70.
17. Ahmad T, Wallace GR, James T, et al. Mapping the HLA association in Behçet’s disease: a role for tumor necrosis factor polymorphisms? Arthritis Rheum. 2003;48:807–13.
18. Baskan EB, Yilmaz E, Saricaoglu H, et al. Detection of parvovirus B19 DNA in the lesional skin of patients with Behçet’s disease. Clin Exp Dermatol. 2007;32:186–90.
19. Mizuki N, Meguro A, Tohnai I, Gül A, Ohno S, Mizuki N. Association of major histocompatibility complex class I chain-related gene A and HLA-B alleles with Behçet’s disease in Turkey. Jpn J Ophthalmol. 2007;51:431–6.
20. Ermakova NA, Alekberova ZS, Prokaeva TB, Poljanskaja IB. Frequency of HLA in patients with Behçet’s disease and association with occlusive retinal vasculitis. Adv Exp Med Biol. 2003;528:231–3.
21. Choukri F, Chakib A, Himmich H, Marih L, Caillat-Zucman S. HLA-B phenotype modifies the course of Behçet’s disease in Moroccan patients. Tissue Antigens. 2003;61:92–6.
22. Gül A, Uyar FA, Inanc M, et al. Lack of association of HLA-B*51 with a severe disease course in Behçet’s disease. Rheumatology (Oxford). 2001;40:668–72.
23. Akpolat T, Koç Y, Yeniay I, et al. Familial Behçet’s disease. Eur J Med. 1992;1:391–5.
24. Koné-Paut I, Geisler I, Wechsler B, et al. Familial aggregation in Behçet’s disease: high frequency in siblings and parents of pediatric probands. J Pediatr. 1999;135:89–93.
25. Direskeneli H, Hasan A, Shinnick T, et al. Recognition of B-cell epitopes of the 65 kDa HSP in Behçet’s disease. Scand J Immunol. 1996;43:464–71.
26. Suzuki Y, Hoshi K, Matsuda T, Mizushima Y. Increased peripheral blood gamma delta + T cells and natural killer cells in Behçet’s disease. J Rheumatol. 1992;19:588–92.
27. de Smet MD, Ramadan A. Circulating antibodies to inducible heat shock protein 70 in patients with uveitis. Ocul Immunol Inflamm. 2001;9:85–92.
28. Mumcu G, Inanc N, Aydin SZ, Ergun T, Direskeneli H. Association of salivary S. mutans colonisation and mannose-binding lectin deficiency with gender in Behçet’s disease. Clin Exp Rheumatol. 2009;27:S32–6.
29. Yokota K, Hayashi S, Fujii N, et al. Antibody response to oral streptococci in Behçet’s disease. Microbiol Immunol. 1992;36:815–22.
30. Isogai E, Ohno S, Kotake S, et al. Chemiluminescence of neutrophils from patients with Behçet’s disease and its correlation with an increased proportion of uncommon serotypes of Streptococcus sanguis in the oral flora. Arch Oral Biol. 1990;35:43–8.
31. Calgüneri M, Ertenli I, Kiraz S, Erman M, Celik I. Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behçet’s disease. Dermatology. 1996;192:125–8.
32. Hirohata S, Oka H, Mizushima Y. Streptococcal-related antigens stimulate production of IL6 and interferon-gamma by T cells from patients with Behcet’s disease. Cell Immunol. 1992;140:410–9.
33. Mochizuki M, Suzuki N, Takeno M, Nagafuchi H, Harada T, Kaneoka H. Fine antigen specificity of human gamma delta T cell lines (V gamma 9 +) established by repetitive stimulation with a serotype (KTH-1) of a gram-positive bacterium, Streptococcus sanguis. Eur J Immunol. 1994;24:1536–43.
34. Evereklioglu C, Er H, Türköz Y, Cekmen M. Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet’s disease. Mediat Inflamm. 2002;11:87–93.
35. Tanaka T, Yamakawa N, Koike N, Suzuki J, Mizuno F, Usui M. Behçet’s disease and antibody titers to various heatshock protein 60s. Ocul Immunol Inflamm. 1999;7:69–74.
36. Apan TZ, Gürsel R, Dolgun A. Increased seropositivity of Helicobacter pylori cytotoxin associated gene-A in Behçet’s disease. Clin Rheumatol. 2007;26:885–9.
37. Evereklioglu C. Current concepts in the etiology and treatment of Behçet disease. Surv Ophthalmol. 2005;50:297–350.
38. Baskan EB, Yilmaz E, Saricaoglu H, et al. Detection of parvovirus B19 DNA in the lesional skin of patients with Behçet’s disease. Clin Exp Dermatol. 2007;32:186–90.
39. Mumcu G, Inanc N, Aydin SZ, Ergun T, Direskeneli H. Association of salivary S. mutans colonisation and mannose-binding lectin deficiency with gender in Behçet’s disease. Clin Exp Rheumatol. 2009;27:S32–6.
40. Inanc N, Mumcu G, Birtas E, et al. Serum mannose-binding lectin levels are decreased in behcet’s disease and associated with disease severity. J Rheumatol. 2005;32:287–91.
41. Yavuz S, Elbir Y, Tulunay A, Eksioglu-Demiralp E, Direskeneli H. Differential expression of toll-like receptor 6 on granulocytes and monocytes implicates the role of microorganisms in Behcet’s disease etiopathogenesis. Rheumatol Int. 2008;28:401–6.
42. Seoudi N, Bergmeier LA, Hagi-Pavli E, Bibby D, Curtis MA, Fortune F. The role of TLR2 and 4 in Behcet’s disease pathogenesis. Innate Immun. 2014;20(4):412–22.
43. Liu X, Wang C, Ye Z, Kijlstra A, Yang P. Higher expression of toll-like receptors 2, 3, 4, and 8 in ocular Behcet’s disease. Investig Ophthalmol Vis Sci. 2013;54:6012–7.
44. Do JE, Kwon SY, Park S, Lee ES. Effects of vitamin D on expression of toll-like receptors of monocytes from patients with Behcet’s disease. Rheumatology (Oxford). 2008;47:840–8.
45. Liang L, Tan X, Zhou Q, et al. IL-1β triggered by peptidoglycan and lipopolysaccharide through TLR2/4 and ROS-NLRP3 inflammasome-dependent pathways is involved in ocular Behçet’s disease. Investig Ophthalmol Vis Sci. 2013;54:402–14.
46. Direskeneli H. Behçet’s disease: infectious aetiology, new autoantigens, and HLA-B51. Ann Rheum Dis. 2001;60:996–1002.
47. Erkiliç K, Evereklioglu C, Cekmen M, Ozkiris A, Duygulu F, Dogan H. Adenosine deaminase enzyme activity is increased and negatively correlates with catalase, superoxide dismutase and glutathione peroxidase in patients with Behçet’s disease: original contributions/clinical and laboratory investigations. Mediat Inflamm. 2003;12:107–16.
48. Calis M, Ates F, Yazici C, et al. Adenosine deaminase enzyme levels, their relation with disease activity, and the effect of colchicine on adenosine deaminase levels in patients with Behçet’s disease. Rheumatol Int. 2005;25:452–6.
49. Canpolat F, Unver M, Eskioğlu F, Kösebalaban S, Durmazlar SP. Serum and erythrocyte adenosine deaminase activities in patients with Behçet’s disease. Int J Dermatol. 2006;45:1053–6.
50. Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K. Cytokine profile in Behçet’s disease patients. Relationship with disease activity. Scand J Rheumatol. 2002;31:205–10.
51. Raziuddin S, Al-Dalaan A, Bahabri S, Siraj AK, Al-Sedairy S. Divergent cytokine production profile in Behçet’s disease. Altered Th1/Th2 cell cytokine pattern. J Rheumatol. 1998;25:329–33.
52. Dalghous AM, Freysdottir J, Fortune F. Expression of cytokines, chemokines, and chemokine receptors in oral ulcers of patients with Behcet’s disease (BD) and recurrent aphthous stomatitis is Th1-associated, although Th2-association is also observed in patients with BD. Scand J Rheumatol. 2006;35:472–5.
53. Sugi-Ikai N, Nakazawa M, Nakamura S, Ohno S, Minami M. Increased frequencies of interleukin-2- and interferon-gamma-producing T cells in patients with active Behçet’s disease. Invest Ophthalmol Vis Sci. 1998;39:996–1004.
54. Frassanito MA, Dammacco R, Cafforio P, Dammacco F. Th1 polarization of the immune response in Behçet’s disease: a putative pathogenetic role of interleukin-12. Arthritis Rheum. 1999;42:1967–74.
55. Boiardi L, Salvarani C, Casali B, et al. Intercellular adhesion molecule-1 gene polymorphisms in Behçet’s disease. J Rheumatol. 2001;28:1283–7.
56. Ben Ahmed M, Houman H, Miled M, et al. Involvement of chemokines and Th1 cytokines in the pathogenesis of mucocutaneous lesions of Behçet’s disease. Arthritis Rheum. 2004;50:2291–5.
57. Bardak Y, Aridogan BC. The demonstration of serum interleukin 6-8, tumor necrosis factor alpha, complement, and immunoglobulin levels in Behçet’s disease with ocular involvement. Ocul Immunol Inflamm. 2004;12:53–8.
58. Suzuki N, Nara K, Suzuki T. Skewed Th1 responses caused by excessive expression of Txk, a member of the Tec family of tyrosine kinases, in patients with Behcet’s disease. Clin Med Res. 2006;4:147–51.
59. Imamura Y, Kurokawa MS, Yoshikawa H, et al. Involvement of Th1 cells and heat shock protein 60 in the pathogenesis of intestinal Behcet’s disease. Clin Exp Immunol. 2005;139:371–8.
60. Turan B, Gallati H, Erdi H, Gürler A, Michel BA, Villiger PM. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Bechçet’s disease; soluble TNFR-75 as a biological marker of disease activity. J Rheumatol. 1997;24:128–32.
61. Katsantonis J, Adler Y, Orfanos CE, Zouboulis CC. Adamantiades-Behçet’s disease: serum IL-8 is a more reliable marker for disease activity than C-reactive protein and erythrocyte sedimentation rate. Dermatology. 2000;201:37–9.
62. Musabak U, Pay S, Erdem H, et al. Serum interleukin-18 levels in patients with Behçet’s disease. Is its expression associated with disease activity or clinical presentations? Rheumatol Int. 2006;26:545–50.
63. Turan B, Pfister K, Diener PA, et al. Soluble tumour necrosis factor receptors sTNFR1 and sTNFR2 are produced at sites of inflammation and are markers of arthritis activity in Behçet’s disease. Scand J Rheumatol. 2008;37:135–41.
64. Durmazlar SP, Ulkar GB, Eskioglu F, Tatlican S, Mert A, Akgul A. Significance of serum interleukin-8 levels in patients with Behcet’s disease: high levels may indicate vascular involvement. Int J Dermatol. 2009;48:259–64.
65. Bardak Y, Aridogan BC. The demonstration of serum interleukin 6-8, tumor necrosis factor-alpha, complement, and immunoglobulin levels in Behçet’s disease with ocular involvement. Ocul Immunol Inflamm. 2004;12:53–8.
66. Ozdamar Y, Berker N, Bahar G, et al. Inflammatory mediators and posterior segment involvement in ocular Behcet disease. Eur J Ophthalmol. 2009;19:998–1003.
67. Akman-Demir G, Tüzün E, Içöz S, Yeşilot N, et al. Interleukin-6 in neuro-Behçet’s disease: association with disease subsets and long-term outcome. Cytokine. 2008;44:373–6.
68. Sugita S, Kawazoe Y, Imai A, Yamada Y, Horie S, Mochizuki M. Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behçet’s disease. Arthritis Res Ther. 2012;14:R99.
69. Shimizu J, Takai K, Fujiwara N, et al. Excessive CD4 + T cells co-expressing interleukin-17 and interferon-γ in patients with Behçet’s disease. Clin Exp Immunol. 2012;168:68–74.
70. Hamzaoui K. Th17 cells in Behçet’s disease: a new immunoregulatory axis. Clin Exp Rheumatol. 2011;29:S71–6.
71. Geri G, Terrier B, Rosenzwajg M, et al. Critical role of IL-21 in modulating TH17 and regulatory T cells in Behçet disease. J Allergy Clin Immunol. 2011;128:655–64.
72. Liang L, Wang H, Peng XY, Zhao M. The changes of Th lymphocyte subsets in patients with Behcet disease. Zhonghua Yan Ke Za Zhi. 2011;47:393–7.
73. Lee YJ, Horie Y, Wallace GR, et al. Genome-wide association study identifies GIMAP as a novel susceptibility locus for Behcet’s disease. Ann Rheum Dis. 2013;72:1510–6.
74. Gunesacar R, Erken E, Bozkurt B, et al. Analysis of CD28 and CTLA-4 gene polymorphisms in Turkish patients with Behcet’s disease. Int J Immunogenet. 2007;34:45–9.
75. Park KS, Baek JA, Do JE, Bang D, Lee ES. CTLA4 gene polymorphisms and soluble CTLA4 protein in Behcet’s disease. Tissue Antigens. 2009;74:222–7.
76. Ben Dhifallah I, Chelbi H, Braham A, Hamzaoui K, Houman MH. CTLA-4 +49A/G polymorphism is associated with Behçet’s disease in a Tunisian population. Tissue Antigens. 2009;73:213–7.
77. Sugita S, Kawazoe Y, Imai A, Yamada Y, Horie S, Mochizuki M. Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behçet’s disease. Arthritis Res Ther. 2012;14:R99.
78. Pay S, Erdem H, Pekel A, et al. Synovial proinflammatory cytokines and their correlation with matrix metalloproteinase-3 expression in Behçet’s disease. Does interleukin-1beta play a major role in Behçet’s synovitis? Rheumatol Int. 2006;26:608–13.
79. Suh CH, Park YB, Song J, Lee CH, Lee SK. Oligoclonal B lymphocyte expansion in the synovium of a patient with Behçet’s disease. Arthritis Rheum. 2001;44:1707–12.
80. Eksioglu-Demiralp E, Kibaroglu A, Direskeneli H, et al. Phenotypic characteristics of B cells in Behçet’s disease: increased activity in B cell subsets. J Rheumatol. 1999;26:826–32.
81. Aydìntug AO, Tokgöz G, D’Cruz DP, et al. Antibodies to endothelial cells in patients with Behçet’s disease. Clin Immunol Immunopathol. 1993;67:157–62.
82. Direskeneli H, Keser G, D’Cruz D, et al. Anti-endothelial cell antibodies, endothelial proliferation and von Willebrand factor antigen in Behçet’s disease. Clin Rheumatol. 1995;14:55–61.
83. Mahesh SP, Li Z, Buggage R, et al. Alpha tropomyosin as a self-antigen in patients with Behçet’s disease. Clin Exp Immunol. 2005;140:368–75.
84. Mor F, Weinberger A, Cohen IR. Identification of alpha-tropomyosin as a target self-antigen in Behçet’s syndrome. Eur J Immunol. 2002;32:356–65.
85. Espinosa G, Font J, Tàssies D, Vidaller A, et al. Vascular involvement in Behçet’s disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med. 2002;112:37–43.
86. Evereklioglu C, Turkoz Y, Er H, Inaloz HS, Ozbek E, Cekmen M. Increased nitric oxide production in patients with Behçet’s disease: is it a new activity marker? J Am Acad Dermatol. 2002;46:50–4.
87. Evereklioglu C, Cekmen M, Ozkiriş A, Karabaş L, Caliş M. The pathophysiological significance of red blood cell nitric oxide concentrations in inflammatory Behçet’s disease. Mediat Inflamm. 2003;12:255–6.
88. Yilmaz G, Sizmaz S, Yilmaz ED, Duman S, Aydin P. Aqueous humor nitric oxide levels in patients with Behçet disease. Retina. 2002;22:330–5.
89. Buldanlioglu S, Turkmen S, Ayabakan HB, et al. Nitric oxide, lipid peroxidation and antioxidant defence system in patients with active or inactive Behçet’s disease. Br J Dermatol. 2005;153:526–30.
90. Duygulu F, Evereklioglu C, Calis M, Borlu M, Cekmen M, Ascioglu O. Synovial nitric oxide concentrations are increased and correlated with serum levels in patients with active Behçet’s disease: a pilot study. Clin Rheumatol. 2005;24:324–30.
91. Cekmen M, Evereklioglu C, Er H, et al. Vascular endothelial growth factor levels are increased and associated with disease activity in patients with Behçet’s syndrome. Int J Dermatol. 2003;42:870–5.
92. Hamzaoui K, Ayed K, Hamza M, Hamzaoui A. VEGF and mRNA VEGF expression in CSF from Behçet’s disease with neurological involvement. J Neuroimmunol. 2009;213:148–53.
93. Espinosa G, Font J, Tàssies D, et al. Vascular involvement in Behçet’s disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med. 2002;112:37–43.
94. Haznedaroglu IC, Ozcebe O, Celik I, Dündar SV, Kirazhi S. Haemostatic markers of procoagulant imbalance in Behçet’s disease. Eur J Haematol. 1996;57:107–8.
95. Akar S, Ozcan MA, Ateş H, et al. Circulated activated platelets and increased platelet reactivity in patients with Behçet’s disease. Clin Appl Thromb Hemost. 2006;12:451–7.
96. Yurdakul S, Hekim N, Soysal T, et al. Fibrinolytic activity and d-dimer levels in Behçet’s syndrome. Clin Exp Rheumatol. 2005;23:S53–8.
97. Itoh R, Takenaka T, Okitsu-Negishi S, Matsushima K, Mizoguchi M. Interleukin 8 in Behçet’s disease. J Dermatol. 1994;21:397–404.
98. Al-Dalaan A, Al-Sedairy S, Al-Balaa S, et al. Enhanced interleukin 8 secretion in circulation of patients with Behçet’s disease. J Rheumatol. 1995;22:904–7.
99. Sahin S, Akoğlu T, Direskeneli H, Sen LS, Lawrence R. Neutrophil adhesion to endothelial cells and factors affecting adhesion in patients with Behçet’s disease. Ann Rheum Dis. 1996;55:128–33.
100. Triolo G, Accardo-Palumbo A, Triolo G, Carbone MC, Ferrante A, Giardina E. Enhancement of endothelial cell E-selectin expression by sera from patients with active Behçet’s disease: moderate correlation with antiendothelial cell antibodies and serum myeloperoxidase levels. Clin Immunol. 1999;91:330–7.
101. Kawakami T, Ohashi S, Kawa Y, et al. Elevated serum granulocyte colony-stimulating factor levels in patients with active phase of sweet syndrome and patients with active behcet disease: implication in neutrophil apoptosis dysfunction. Arch Dermatol. 2004;140:570–4.
102. Hamzaoui K, Maître B, Hamzaoui A. Elevated levels of MMP-9 and TIMP-1 in the cerebrospinal fluid of neuro-Behçet’s disease. Clin Exp Rheumatol. 2009;27:S52–7.
103. Hatemi G, Yazici Y, Yazici H. Behçet’s syndrome. Rheum Dis Clin North Am. 2013;39(2):245–61.
104. Yamashita N, Kaneoka H, Kaneko S, Takeno M, et al. Role of gammadelta T lymphocytein the development of Behcet’s disease. Clin Exp Rheum. 1997;107:241–7.
105. Hasan A, Fortune F, Wilson A, et al. Role of T-cells in pathogenesis and diagnosis of Behcet’s Dis. Lancet. 1996;347:789–94.
106. Zouboulis CC, Vaiopoulos G, Marcomichelakis N, et al. Onset signs, clinical course, prognosis, treatment and outcome of adult patients with Adamantiades-Behçet’s disease in Greece. Clin Exp Rheumatol. 2003;21:S19–26.
107. O’Duffy JD. Behcet’s syndrome. In: Primer on the rheumatic diseases, 10th, Arthritis Foundation, Atlanta 1993. vol. 29, p. 206.
108. Kaklamani VG, Vaiopoulos G, Markomichelakis N, Kaklamanis P. Recurrent epididymo-orchitis in patients with Behçet’s disease. J Urol. 2000;163:487–9.
109. Cho YH, Jung J, Lee KH, Bang D, Lee ES, Lee S. Clinical features of patients with Behçet’s disease and epididymitis. J Urol. 2003;170:1231–3.
110. Diri E, Mat C, Hamuryudan V, Yurdakul S, Hizli N, Yazici H. Papulopustular skin lesions are seen more frequently in patients with Behçet’s syndrome who have arthritis: a controlled and masked study. Ann Rheum Dis. 2001;60:1074–6.
111. Tunc R, Keyman E, Melikoglu M, Fresko I, Yazici H. Target organ associations in Turkish patients with Behçet’s disease: a cross sectional study by exploratory factor analysis. J Rheumatol. 2002;29:2393–6.
112. Hatemi G, Bahar H, Uysal S, et al. The pustular skin lesions in Behcet’s syndrome are not sterile. Ann Rheum Dis. 2004;63:1450–2.
113. Jorizzo JL, Solomon AR, Zanolli MD, Leshin B. Neutrophilic vascular reactions. J Am Acad Dermatol. 1988;19:983–1005.
114. Matsuo T, Itami M, Nakagawa H, Nagayama M. The incidence and pathology of conjunctival ulceration in Behçet’s syndrome. Br J Ophthalmol. 2002;86:140–3.
115. Zamir E, Bodaghi B, Tugal-Tutkun I, et al. Conjunctival ulcers in Behçet’s disease. Ophthalmology. 2003;110:1137–41.
116. Koç Y, Güllü I, Akpek G, et al. Vascular involvement in Behçet’s disease. J Rheumatol. 1992;19:402–10.
117. Seyahi E, Melikoglu M, Yazici H. Clinical features and diagnosis of Behcet’s syndrome. Int J Adv Rheumatol. 2007;5:8.
118. Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore). 2003;82:60–76.
119. Uzun O, Akpolat T, Erkan L. Pulmonary vasculitis in behcet disease: a cumulative analysis. Chest. 2005;127:2243–53.
120. Seyahi E, Melikoglu M, Akman C, et al. Pulmonary artery involvement and associated lung disease in Behçet disease: a series of 47 patients. Medicine (Baltimore). 2012;91:35–48.
121. Uzun O, Akpolat T, Erkan L. Pulmonary vasculitis in behcet disease: a cumulative analysis. Chest. 2005;127:2243–53.
122. Sibley C, Yazici Y, Tascilar K, et al. Behçet syndrome manifestations and activity in the United States versus Turkey: a cross-sectional cohort comparison. J Rheumatol. 2014;41(7):1379–84.
123. Bayraktar Y, Balkanci F, Bayraktar M, Calguneri M. Budd–Chiari syndrome: a common complication of Behçet’s disease. Am J Gastroenterol. 1997;92:858–62.
124. Kim HA, Choi KW, Song YW. Arthropathy in Behçet’s disease. Scand J Rheumatol. 1997;26:125–9.
125. Moses Alder N, Fisher M, Yazici Y. Behçet’s syndrome patients have high levels of functional disability, fatigue and pain as measured by a Multi-dimensional Health Assessment Questionnaire (MDHAQ). Clin Exp Rheumatol. 2008;26:S110–3.
126. Akpolat T, Akkoyunlu M, Akpolat I, Dilek M, Odabas AR, Ozen S. Renal Behçet’s disease: a cumulative analysis. Semin Arthritis Rheum. 2002;31:317–37.
127. Goldeli O, Ural D, Komsuoğlu B, Ağaçdiken A, Dursun E, Cetinarslan B. Abnormal QT dispersion in Behçet’s disease. Int J Cardiol. 1997;61:55–9.
128. Huong DL, Wechsler B, Papo T, et al. Endomyocardial fibrosis in Behçet’s disease. Ann Rheum Dis. 1997;56:205–8.
129. Gürgün C, Ercan E, Ceyhan C, et al. Cardiovascular involvement in Behçet’s disease. Jpn HeartJ. 2002;43:389–98.
130. Geri G, Wechsler B, Thi Huong du L, et al. Spectrum of cardiac lesions in Behçet disease: a series of 52 patients and review of the literature. Medicine (Baltimore). 2012;91:25–34.
131. Barnes CG. Treatment of Behcet’s syndrome. Rheumatology (Oxford). 2006;6(45):245–7.
132. Mat C, Yurdakul S, Uysal S, et al. A double-blind trial of depot corticosteroids in Behçet’s syndrome. Rheumatology (Oxford). 2006;45:348–52.
133. Saenz A, Ausejo M, Shea B, Wells G, Welch V, Tugwell P. Pharmacotherapy for Behcet’s syndrome. Cochrane Database Syst Rev. 2000. (doppia nota 140).
134. Yurdakul S, Mat C, Mat C, et al. A double-blind trial of colchicine in Behçet’s syndrome. Arthritis Rheum. 2001;44:2686–92.
135. Kaklamani VG, Kaklamanis PG. Treatment of Behçet’s disease–an update. Semin Arthritis Rheum. 2001;30:299–312.
136. Aktulga E, Altaç M, Müftüoglu A, et al. A double blind study of colchicine in Behçet’s disease. Haematologica. 1980;65:399–402.
137. Kazokoglu H, Saatçi O, Cuhadaroglu H, Eldem B. Long-term effects of cyclophosphamide and colchicine treatment in Behçet’s disease. Ann Ophthalmol. 1991;23:148–51.
138. Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behçet’s syndrome. N Engl J Med. 1990;322:281–5.
139. Saadoun D, Wechsler B, Terrada C, et al. Azathioprine in severe uveitis of Behçet’s disease. Arthritis Care Res (Hoboken). 2010;62:1733–8.
140. Saenz A, Ausejo M, Shea B, Wells G, Welch V, Tugwell P. Pharmacotherapy for Behcet’s syndrome. Cochrane Database Syst Rev. 2000. (doppia nota 133).
141. Ozyazgan Y, Yurdakul S, Yazici H, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet’s syndrome: a single masked trial. Br J Ophthalmol. 1992;76:241–3.
142. Atmaca LS, Batioglu F. The efficacy of cyclosporin-a in the treatment of Behçet’s disease. Ophthalmic Surg. 1994;25:321–7.
143. Sajjadi H, Soheilian M, Ahmadieh H, et al. Low dose cyclosporin-A therapy in Behçet’s disease. J Ocul Pharmacol. 1994;10:553–60.
144. Whitcup SM, Salvo EC Jr, Nussenblatt RB. Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behçet’s disease. Am J Ophthalmol. 1994;118:39–45.
145. BenEzra D, Cohen E, Chajek T, et al. Evaluation of conventional therapy versus cyclosporine A in Behçet’s syndrome. Transpl Proc. 1988;20:136–43.
146. Kötter I, Günaydin I, Batra M, et al. CNS involvement occurs more frequently in patients with Behçet’s disease under cyclosporin A (CSA) than under other medications–results of a retrospective analysis of 117 cases. Clin Rheumatol. 2006;25:482–6.
147. Sajjadi H, Soheilian M, Ahmadieh H, et al. Low dose cyclosporin-A therapy in Behçet’s disease. J Ocul Pharmacol. 1994;10:553–60.
148. Sakane T, Takeno M. Novel approaches to Behçet’s disease. Expert Opin Investig Drugs. 2000;9:1993–2005.
149. Pipitone N, Olivieri I, Cantini F, Triolo G, Salvarani C. New approaches in the treatment of Adamantiades-Behçet’s disease. Curr Opin Rheumatol. 2006;18:3–9.
150. Sfikakis PP, Markomichelakis N, Alpsoy E, et al. Anti-TNF therapy in the management of Behcet’s disease—review and basis for recommendations. Rheumatology (Oxford). 2007;46:736.
151. Sfikakis PP, Kaklamanis PH, Elezoglou A, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease. Ann Intern Med. 2004;140:404–6.
152. Lee JH, Cheon JH, Jeon SW, et al. Efficacy of infliximab in intestinal Behçet’s disease: a Korean multicenter retrospective study. Inflamm Bowel Dis. 2013;19:1833–8.
153. Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Behçet’s disease: a double blind, placebo controlled study. J Rheumatol. 2005;32:98–105.
154. Bawazeer A, Raffa LH, Nizamuddin SH. Clinical experience with adalimumab in the treatment of ocular Behçet disease. Ocul Immunol Inflamm. 2010;18:226–32.
155. Pivetti-Pezzi P, Accorinti M, Pirraglia MP, Priori R, Valesini G. Interferon alpha for ocular Behçet’s disease. Acta Ophthalmol Scand. 1997;75:720–2.
156. Nichols JC, Ince A, Akduman L, Mann ES. Interferon-alpha 2a treatment of neuro-Behcet disease. J Neuroophthalmol. 2001;21:109–11.
157. Zouboulis CC, Orfanos CE. Treatment of Adamantiades-Behçet disease with systemic interferon alfa. Arch Dermatol. 1998;134:1010–6.
158. Hamuryudan V, Moral F, Yurdakul S, et al. Systemic interferon alpha 2b treatment in Behçet’s syndrome. J Rheumatol. 1994;21:1098–100.
159. Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol. 2002;138:467–71.
160. Deuter CM, Kötter I, Kötter I, Günaydin I, Zierhut M, Stübiger N. Ocular involvement in Behçet’s disease: first 5-year results for visual development after treatment with interferon alfa-2a. Ophthalmologe. 2004;101:129–34.
161. Kötter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Behçet’s disease with sight threatening posterior or panuveitis. Br J Ophthalmol. 2003;87:423–31.
162. Alpsoy E, Yilmaz E, Basaran E. Interferon therapy for Behçet’s disease. J Am Acad Dermatol. 1994;31:617–9.
163. O’Duffy JD, Calamia K, Cohen S, et al. Interferon-alpha treatment of Behçet’s disease. J Rheumatol. 1998;25:1938–44.
164. Kuemmerle-Deschner JB, Tzaribachev N, Deuter C, Zierhut M, Batra M, Koetter I. Interferon-alpha-a new therapeutic option in refractory juvenile Behçet’s disease with CNS involvement. Rheumatology. 2008;47:1051.
165. Yalçindag FN, Uzun A. Results of interferon alpha-2a therapy in patients with Behcet’s disease. J Ocul Pharmacol Ther. 2012;28:439.
166. Kötter I, Günaydin I, Zierhut M, Stübiger N. The use of interferon alpha in Behçet disease: review of the literature. Semin Arthritis Rheum. 2004;33:320.
167. Shugaiv E, Tüzün E, Mutlu M, Kiyat-Atamer A, Kurtuncu M, Akman-Demir G. Mycophenolate mofetil as a novel immunosuppressant in the treatment of neuro-Behçet’s disease with parenchymal involvement: presentation of four cases. Clin Exp Rheumatol. 2011;29:S64–7.
168. Adler YD, Mansmann U, Zouboulis CC. Mycophenolate mofetil is ineffective in the treatment of mucocutaneous Adamantiades-Behçet’s disease. Dermatology. 2001;203:322–4.
169. Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;128:443–50.
170. Davatchi F, Shams H, Rezaipoor M, et al. Rituximab in intractable ocular lesions of Behcet’s disease; randomized single-blind control study (pilot study). Int J Rheum Dis. 2010;13:246.
171. Seider N, Beiran I, Scharf J, Miller B. Intravenous immunoglobulin therapy for resistant ocular Behçet’s disease. Br J Ophthalmol. 2001;85:1287.
172. Tellier Z. Intravenous immunoglobulin in eye involvement. Clin Rev Allergy Immunol. 2005;29:295–306.
173. Akman-Demir G, Serdaroglu P, Tasçi B. Clinical patterns of neurological involvement in Behçet’s disease: evaluation of 200 patients. The Neuro-Behçet Study Group. Brain. 1999;122(Pt 11):2171–82.
174. Kidd D, Steuer A, Denman AM, Rudge P. Neurological complications in Behcet’s syndrome. Brain. 1999;122:2183–94.
175. Siva A, Kantarci OH, Saip S, et al. Behcet’s disease: diagnostic and prognostic aspects of neurological involvement. J Neurol. 2001;248:95–103.
176. Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Behcet’s syndrome: a 2-decade outcome survey of 387 patients followed at dedicated center. Medicine. 2003;82:60.
177. Wechsler B, Vidailhet M, Piette JC, et al. Cerebral venous sinus thrombosis in Behcet’s disease: long term follow up of 25 cases. Neurology. 1992;42:614–8.
178. Serdaroglou P. Behcet’s disease and the nervous system. J Neurol. 1998;245:197–205.
179. Siva A, Altintas A, Saip S. Behcet’s disease and the nervous system. Curr Opin Neurol. 2004;17:347–57.
180. Oktem-Tanor O, Baykan-Kurt B, Gürvit IH, Akman-Demir G, Serdaroğlu P. Neuropsychological follow up of 12 patients with neuro-Behcet’s disease. J Neurol. 1999;246:113–9.
181. Al-Araji A, Kidd DP. Neuro-Behcet’s disease: epidemiology, clinical characteristics and management. Lancet Neurol. 2009;8:192–204.
182. Siva A, Saip S. The spectrum of the nervous system in Neurobehcet’s syndrome and its differential diagnosis. J Neurol. 2009;256:513–29.
183. Saip S, Akman-Demir G, Siva A. Neuro-Behçet syndrome. Handb Clin Neurol. 2014;121:1703–23.
184. Saip S, Siva A, Altintas A, et al. Headache in Behcet’s syndrome. Headache 2005;45:911–9.
185. Namer IJ, Karabudak R, Zileli T, Ruacan S, Küçükali T, Kansu E. Peripheral nervous system involvement in Behcet’s disease. Eur Neurol. 1987;26:235–40.
186. Lannuzel A, Lamaury I, Charpentier D, Caparros-Lefebvre D. Neurological manifestation in Behcet’s disease in Carribean population: clinical and imaging findings. J Neurol. 2002;249:410–8.
187. Sarui H, Maruyama T, Ito I, et al. Necrotising miositi in Behcet’s disease: characteristics on magnetic resonance imaging and a review of the literature. Ann Rheum Dis. 2002;61:751–2.
188. Atasoy HT, Tunc TO, Unal AE, et al. Peripheral nervous system involvement in Behcet’s disease in patients with Behcet’s disease. Neurologist. 2007;13:225–30.
189. Siva A, Altintas A, Saip S. Behcet’s syndrome and the nervous system. Curr Opin Neurol. 2004;17:347–57.
190. Hirohata S, Isshi K, Oguchi H, et al. Cerebrospinal fluid IL6 in progressive neuro-behcet’s syndrome. Clin Immunol Immunopathol. 1997;82:12–7.
191. Kawai M, Hirohata S. Cerebrospinal fluid beta(2)-microglobulin in neuro-Behcet’s syndrome. J Neurol Sci. 2000;179:132–9.
192. Saadoun D, Wechsler B, Resche-Rigon M, et al. Cerebral venous thrombosis in Behcet’s disease. Arthritis Rheum. 2009;61:518–26.
193. Yesilot N, Bahar S, Yilmazer S, et al. Cerebral venous thrombosis in Behcet’s disease compared to those associated to other etiologies. J Neurol. 2009;256:1134–42.
194. Houman MH, Hamzaoui-B’Chir S, Ben GI, et al. Neurologic manifestations of Behcet’s disease: analysis of a series of 27 patients. Rev Med Interne. 2002;23:592–606.
195. Bahar S, Coban O, Gürvit IH, Akman-Demir G, Gökyiğit A. Spontaneous dissection of the extracranial vertebral artery with spinal subarachnoid hemorrhage in a patient with Behcet’s disease. Neuroradiology. 1993;35:352–4.
196. Krespi Y, Akman-Demir G, Poyraz M, et al. Cerebral vasculitis and ischaemic stroke in Behcet’s disease: report of one case and review of the literature. Eur J Neurol. 2001;8:719–22.
197. Sagduyu A, Sirin H, Oksel F, Turk T, Ozenc D. An unusual case of Behcet disease presenting with bilateral internal carotid artery occlusion. J Neurol Neurosurg Psychiatry. 2002;73:343.
198. Kizilkilic O, Albayram S, Adaletli I, Ak H, Islak C, Kocer N. Endovascular treatment of Behcet’s disease associated intracranial aneurysm: report of 2 cases and review of the literature. Neuroradiology. 2003;45:328–34.
199. Aktas EG, Kaplan M, Ozveren MF. Basilar artery aneurysm associated with Behcet’s disease: a case report. Turk Neurosurg. 2008;18:35–8.
200. Hirohata S. Hystopathology of central nervous system lesions in Behcet’s disease. J Neurol Sci. 2008;267:41–7.
201. Hadfield MG, Aydin F, Lippman HR, Kubal WS, Sanders KM. Neurobehcet’s disease. Clin Neuropathol. 1996;15:249–55.
202. Arai Y, Kohno S, Takahashi Y, Miyajima Y, Tsutusi Y. Autopsy case of neuro-Behcet’s disease with multifocal neutrophilic perivascular inflammation. Neuropathology. 2006;26:579–85.
203. Kessler JA, Ludlam WH, Freidin MM, et al. Cytokine-induced programmed death of cultured sympathetic neurons. Neuron. 1993;11:1123–32.
204. Heyser CJ, Masliah E, Samimi A, Campbell IL, Gold LH. Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing IL6 in the brain. Proct Natl Acad Sci. 1997;94:1500–5.
205. Gruol DL, Nelson TE. Purkinje neuron physiology is altered by the inflammatory factor IL6. Cerebellum. 2005;4:198–205.
206. Kocer N, Islak C, Siva A, et al. CNS involvement in neurobehcet’s syndrome: an MR study. AJNR. 1999;20:1015–24.
207. Siva A, Fresko I. Behcet’s disease. Curr Treat Options Neurol. 2000;2:435–48.
208. Siva A, Kantarci OH, Saip S, et al. Behçet’s disease: diagnostic and prognostic aspects of neurological involvement. J Neurol. 2001;248(2):95–103.
209. Sakane T, Takeno M, Suzuki N, Inaba G. Behcet’s disease. N Engl Med. 1999;341:1284–91.
210. Hirohata S. Is the long-term use of systemic corticosteroids beneficial in the management of Behçet’s syndrome? Nat Clin Pract Rheumatol. 2006;2(7):358–9.
211. Kotake S, Higashi K, Yoshikawa K, Sasamoto Y, Okamoto T, Matsuda H. Central nervous system symptoms in patients with Bechet’s disease receiving cyclosporine therapy. Opthalmology. 1999;106:586.
212. Mitsui Y, Mitsui M, Urakami R, Kihara M, Takahashi M, Kusunoki S. Behcet’s disease presenting with neurological complication immediately after convention from conventional cyclosporine A to microemulsion formulation. Intern Med. 2005;44:149–52.
213. Kotter I, Günaydin I, Batra M, et al. CNS involvement occurs more frequently in patients with Behcet’s disease under cyclosporin A than under other medications results of a retrospective analysis of 117 cases. Clin Rheumatol. 2006;25:482–6.
214. Kikuchi H, Aramaki K, Hirohata S. Low dose of MTX for progressive neuro-Behcet’s disease. A follow up study for 4 years. Adv Exp Med Biol. 2003;528:575–8.
215. Licata G, Pinto A, Tuttolomondo A, et al. Anti-TNF alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behcet’s syndrome. Ann Rheum Dis. 2003;62:280–1.
216. Ribi C, Sztajzel R, Delavelle J, Chizzolini C. Efficacy of TNF alpha blockade in cyclophosphamide resistant neuro-behcet’s disease. Neurol Neurosurg Psychiatry. 2005;76:1733–5.
217. Sarwar H, McGrath H Jr, Espinoza LR. Successful treatment of long-standing neurobehcet’s disease with infliximab in patients with refractory disease. J Rheumatol. 2005;32:181–3.
218. Fujikawa K, Aratake K, Kawakami A, et al. Successful treatment of refractory neurobehcet’s disease with infliximab: a case report to show its efficacy by MR imaging, transcranial magnetic stimulation and CK profile. Ann Rheum Dis. 2007;66:136–7.
219. Pipitone N, Olivieri I, Padula A, et al. Infliximab for the treatment of neuro-Behcet’s disease: a case series and review of the literature. Arthritis Rheum. 2008;59:285–90.
220. Kikuchi H, Aramaki K, Hirohata S. Effect of Infliximab in progressive Neuro-Behcet’s syndrome. J Neurol Sci. 2008;272:99–105.